Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized study of D-beta-hydroxybutyrate in healthy volunteers and patients with depression
jRCTs061200006Completed
- Sponsor
- Osaka Gas
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of 3-hydroxybutyrate in major depressive disorder (MDD) (2 arms), sponsored by Osaka Gas. Primary endpoint: Change in MADRS total score. Started Jun 2020; status: completed.
02
Drugs
3-hydroxybutyrate
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCTs061200006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061200006.